Univariate logistic regression analysis of antibody response after COVID-19 mRNA vaccination in patients.
OR | 95% CI | P | |
---|---|---|---|
Univariate logistic regression analysis | |||
Sex, female (ref) | 0.91 | 0.50–1.67 | 0.77 |
Age, yrs | 0.98 | 0.96–1.00 | 0.09 |
Time from vaccination to blood sample, days | 1.00 | 0.99–1.01 | 0.61 |
Diagnosis | |||
Rheumatoid arthritis | Ref | Ref | Ref |
Systemic lupus erythematosus | 0.57 | 0.19–1.69 | 0.31 |
AAV (GPA/EGPA) | 0.83 | 0.41–1.69 | 0.61 |
Polymyositis/dermatomyositis | 0.36 | 0.13–1.02 | 0.06 |
Systemic sclerosis | 1.33 | 0.35–5.07 | 0.67 |
Other RDs | 2.67 | 0.82–8.71 | 0.10 |
RTX exposure | |||
RTX treatment within last 15 months | 0.21 | 0.10–0.40 | < 0.001 |
Time between last RTX and vaccination, months | 1.06 | 1.03–1.09 | < 0.001 |
Total no. of RTX infusions | 0.96 | 0.92–1.01 | 0.10 |
Total RTX dose, mg | 0.97 | 0.92–1.02 | 0.18 |
Time from first to last RTX treatment, months | 1.00 | 1.00–1.00 | 0.57 |
DMARD treatment | |||
None | 0.94 | 0.50–1.78 | 0.85 |
Prednisone, yes/no (no = ref) | 0.49 | 0.27–0.89 | 0.02 |
Prednisone dose, mg | 0.91 | 0.85–0.99 | 0.02 |
Methotrexate | 1.71 | 0.90–3.25 | 0.10 |
Hydroxychloroquine | 0.87 | 0.35–2.19 | 0.77 |
Azathioprine | 0.23 | 0.06–0.80 | 0.02 |
Multivariate logistic regression analysis | |||
Time between last RTX and vaccination, months | 1.08 | 1.04–1.11 | < 0.001 |
DMARD treatment | |||
Prednisone dose, mg | 0.91 | 0.84–0.99 | 0.03 |
Azathioprine | 0.10 | 0.02–0.44 | 0.002 |
Explanatory variables in the univariate model are based on previous knowledge of association to vaccination response and evaluation of RTX exposure. Specific DMARD treatments were included if ≥ 10% of the patients received it. The multivariate model includes all explanatory variables with statistically significant effects in the univariate analysis. “Time from last RTX treatment to vaccination” and “prednisone treatment” were included as continuous variables. Values in bold are statistically significant. AAV: antineutrophil cytoplasmic antibody–associated vasculitis; COVID-19: coronavirus disease 2019; DMARD: disease-modifying antirheumatic drug; EGPA: eosinophilic granulomatosis with polyangiitis; GPA: granulomatosis with polyangiitis; OR: odds ratio; RD: rheumatic disease; RTX: rituximab.